Differences in Anaphylaxis Reporting Among Cephalosporins: Analysis of the FDA Adverse Event Reporting System Database

被引：0
|
作者：
Shah, Divya [1 ]
Stone, Cosby [2 ]
Rukasin, Christine [3 ]
机构：
[1] Univ Arizona, Coll Med, Phoenix, AZ USA
[2] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[3] Phoenix Childrens Hosp, Phoenix, AZ USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2024年 / 153卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
233
引用
收藏
页码：AB77 / AB77
页数：1
相关论文
共 50 条
  • [1] Novel adverse events of blonanserin: a disproportionality analysis in the FDA Adverse Event Reporting System database
    Subeesh, Viswam
    Singh, Hemendra
    Maheswari, Eswaran
    Beulah, Thomas
    [J]. MINERVA PSICHIATRICA, 2018, 59 (02): : 105 - 110
  • [2] Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database
    Liu, Ruixue
    Liu, Chunxiao
    Feng, Dianwei
    Guo, Tongxin
    Wang, Ying
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [3] Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database
    Rashid Kazerooni
    Edward P. Armstrong
    [J]. Clinical Drug Investigation, 2018, 38 : 867 - 872
  • [4] Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database
    Kazerooni, Rashid
    Armstrong, Edward P.
    [J]. CLINICAL DRUG INVESTIGATION, 2018, 38 (09) : 867 - 872
  • [5] Botulinum toxin type A overdoses: analysis of the FDA adverse event reporting system database
    Kazerooni, Rashid
    [J]. NEUROLOGY, 2019, 92 (15)
  • [6] Vedolizumab Adverse Events: Analysis of the FDA Adverse Event Reporting System
    Jow, Steven
    Hutfless, Susan
    [J]. INFLAMMATORY BOWEL DISEASES, 2017, 23 : S35 - S36
  • [7] Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database
    Zhu, Jinfeng
    Hu, Mianda
    Liang, Yingshi
    Zhong, Mingjun
    Chen, Zilin
    Wang, Zhenjie
    Yang, Yujia
    Luo, Ziyi
    Zeng, Wenqi
    Li, Jiahui
    Du, Yikuan
    Liu, Yi
    Yang, Chun
    [J]. HELIYON, 2024, 10 (14)
  • [8] Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database A Disproportionality Analysis
    Shamloo, Behrooz K.
    Chhabra, Pankdeep
    Freedman, Andrew N.
    Potosky, Arnold
    Malin, Jennifer
    Smith, Sheila Weiss
    [J]. DRUG SAFETY, 2012, 35 (06) : 507 - 518
  • [9] Adverse event profile differences between rituximab and ocrelizumab: findings from the fda adverse event reporting database
    Caldito, N. Gonzalez
    Shirani, A.
    Salter, A.
    Stuve, O.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 257 - 257
  • [10] Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database
    Caldito, Natalia Gonzalez
    Shirani, Afsaneh
    Salter, Amber
    Stuve, Olaf
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (07) : 1066 - 1076
12345